Petros Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Petros Pharmaceuticals, Inc. (PTPI) reported Net Income (Loss) Available to Common Stockholders, Basic of -$26.80 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2025-03-31
- Petros Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-12-31 was -$10.79M.
- Petros Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$5.25M.
- Petros Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$2.73M.
- Petros Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$8.03M.
- Petros Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$26.80M.
- Petros Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$13.81M.
- Petros Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$20.04M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | -$10.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$16.04M derived: sum of 2 quarters · filed 2025-03-31 | -$18.77M derived: sum of 3 quarters · filed 2025-03-31 | -$26.80M 10-K · filed 2025-03-31 | ||
| 2024-09-30 | -$5.25M 10-Q · filed 2024-11-13 | -$7.98M derived: sum of 2 quarters · filed 2024-11-13 | -$16.01M 10-Q · filed 2024-11-13 | -$19.85M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2024-06-30 | -$2.73M 10-Q · filed 2024-08-14 | -$10.76M 10-Q · filed 2024-08-14 | -$14.60M derived: sum of 3 quarters · filed 2025-03-31 | -$20.64M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2024-03-31 | -$8.03M 10-Q · filed 2024-05-15 | -$11.87M derived: sum of 2 quarters · filed 2025-03-31 | -$17.91M derived: sum of 3 quarters · filed 2025-03-31 | |||
| 2023-12-31 | -$3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$9.88M derived: sum of 2 quarters · filed 2025-03-31 | -$13.81M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$6.04M 10-Q · filed 2024-11-13 | -$4.89M 10-Q · filed 2023-11-15 | -$9.97M 10-Q · filed 2024-11-13 | -$8.82M 10-Q · filed 2023-11-15 | ||
| 2023-03-31 | -$1.39M 10-Q · filed 2024-05-15 | -$5.61M derived: sum of 2 quarters · filed 2024-05-15 | -$19.44M derived: sum of 3 quarters · filed 2024-05-15 | |||
| 2022-12-31 | -$4.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$18.05M derived: sum of 2 quarters · filed 2024-04-01 | -$20.04M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$13.83M 10-Q · filed 2023-11-15 | -$15.82M 10-Q · filed 2023-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |